Cargando…

33. Evaluating the Safety and Effectiveness of a Non-Severe Community-Acquired Pneumonia Pharmacist Pathway

BACKGROUND: One of the main roles of the SSM Health WI Regional Antimicrobial Stewardship Program is to create infection treatment pathways based on the Infectious Diseases Society of America (IDSA) practice guidelines. Treatment pathways are used to guide provider prescribing of antimicrobials for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sylvain, Kelly, Polenska, Jennifer, Levin, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644979/ http://dx.doi.org/10.1093/ofid/ofab466.235

Ejemplares similares

66. Impact of a Pharmacist-Driven Azithromycin De-escalation Protocol for Community-Acquired Pneumonia
por: Shakeraneh, Pegah, et al.
Publicado: (2020)

42. A Pharmacist-Led Intervention to Decrease Anaerobic Coverage for Hospitalized Patients with Community-Acquired Pneumonia
por: Enzmann, Maxx O, et al.
Publicado: (2020)

2603. Acceptance of Pharmacist-Led Stewardship Recommendations for Patients with Community-Acquired Pneumonia
por: Walker, Ramara E, et al.
Publicado: (2023)

Middle molecules in severe community-acquired pneumonia
por: Dumitras, T, et al.
Publicado: (2015)

1484. Microbial Etiology of Community-acquired Pneumonia in Immunocompromised Patients
por: Deshpande, Abhishek, et al.
Publicado: (2020)

169. Development of a Real Time Electronic Algorithm to Identify Hospitalized Patients with Community-Acquired Pneumonia
por: Fabre, Valeria, et al.
Publicado: (2020)

1498. Etiology of Community-acquired Pneumonia in Adults: A Systematic Review
por: Shoar, Saeed, et al.
Publicado: (2020)

1317. Prevalence of Pseudomonas aeruginosa as the Causative Organism for Community Acquired Pneumonia
por: Haviland, Adam D, et al.
Publicado: (2021)

Prognostic assessment in community-acquired pneumonia by pneumonia severity scores and biomarkers
por: Dusemund, F, et al.
Publicado: (2010)

Severe community-acquired pneumonia in the intensive care unit
por: Costa, C, et al.
Publicado: (2005)

Outcome of severe community-acquired pneumonia: the impact of comorbidities
por: Pereira, JM, et al.
Publicado: (2013)

Impact of an Emergency Medicine Pharmacist on Appropriate Empiric Antibiotic Prescribing for Community-Acquired Pneumonia and Intra-Abdominal Infections
por: Kulwicki, Benjamin, et al.
Publicado: (2017)

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002)

2252. Characteristics and Management of non-ICU Patients with Community-Acquired Pneumonia (CAP)
por: Goetz, Matthew B, et al.
Publicado: (2023)

Severe community-acquired pneumonia: risk factors for in-hospital mortality
por: Pereira, JM, et al.
Publicado: (2012)

Severity of illness scoring systems in community-acquired Legionella pneumonia
por: Simonsen, Ø, et al.
Publicado: (2010)

93. Enhanced Oral Care as Prevention for Non-ventilator Hospital Acquired Pneumonia
por: Giuliano, Karen K, et al.
Publicado: (2020)

1499. Incidence of Community Acquired Pneumonia by Age and Comorbid Conditions in the Veterans Health Administration (VHA)
por: Bej, Taissa A, et al.
Publicado: (2020)

803. Risk factors associated with Clostridioides difficile infection in hospitalized patients with community-acquired pneumonia
por: Moore, William Justin, et al.
Publicado: (2020)

100. Assessment of Emergency Department Prescribing Practices for Outpatient Treatment of Urinary Tract Infection, Community-Acquired Pneumonia, and Skin and Soft Tissue Infections
por: Thaller, Matthew, et al.
Publicado: (2021)

A new severity score for community-acquired pneumonia: PARB score
por: Uchiyama, N, et al.
Publicado: (2010)

Severe community acquired pneumonia and ARDS: prognostic factors in infants
por: Chidini, G, et al.
Publicado: (2003)

2210. Nasopharyngeal Detection of Streptococcus pneumoniae and Clinical Disease Severity in Children with Community-Acquired Pneumonia (CAP)
por: Wook Yun, Ki, et al.
Publicado: (2019)

68. Impact of a Pharmacy-Driven Antimicrobial Time-out on Duration of Therapy in Community-Acquired Pneumonia
por: Patel, Amolee R, et al.
Publicado: (2020)

1514. Mortality and Readmission in Adults during the First Year Following Hospitalization for Community-Acquired Pneumonia in the US
por: Sato, Reiko, et al.
Publicado: (2020)

1324. Identification of Local Risk Factors for P. aeruginosa in Community-acquired Pneumonia in a Veteran Population
por: Gibbons, Emily A, et al.
Publicado: (2021)

68. Impact of Streptococcus pneumoniae Urinary Antigen Testing in Patients with Community-Acquired Pneumonia Admitted within a Large Academic Medical System
por: Greenfield, Adam, et al.
Publicado: (2021)

89. Construction of an Electronic Algorithm to Efficiently Target Antimicrobial Stewardship Efforts for Adults Hospitalized with Community-acquired Pneumonia
por: Lautenbach, Ebbing, et al.
Publicado: (2020)

Community-acquired pneumonia treated on the ICU
por: Apostolidou, E, et al.
Publicado: (2006)

1666. A Clinical Care Pathway Improves Antibiotic Prescribing in Hospitalized Children with Community Acquired Pneumonia
por: Schweiger, Jennifer, et al.
Publicado: (2023)

Analysis of the mortality rate in patients admitted to the ICU for severe community-acquired pneumonia
por: Joya-Montosa, C, et al.
Publicado: (2015)

382. Incidence of Hospital-Acquired and Ventilator-Associated Pneumonia in Patients with Severe COVID 19 on High Flow Oxygen
por: Papamanoli, Aikaterini, et al.
Publicado: (2020)

1489. Safety and Performance of a Pharmacist-Driven Nasal MRSA PCR Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia at an Academic Medical Center
por: Meng, Lina, et al.
Publicado: (2020)

1457. Escherichia coli Community Acquired Pneumonia
por: John, Teny Mathew, et al.
Publicado: (2018)

99. Comparison of Procalcitonin Testing to a Targeted Audit-and Feedback Strategy on Prescribed Durations of Therapy for Community-Acquired Pneumonia
por: Clark, Lauren, et al.
Publicado: (2020)

231. Impact of DRIP Score Documentation at Time of Physician Order Entry on Combination Antimicrobials in Treatment of Community Acquired Pneumonia
por: Herbin, Shelbye R, et al.
Publicado: (2020)

Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia
por: Suberviola, B, et al.
Publicado: (2011)

Effects of systemic steroid in patients with severe community-acquired pneumonia requiring mechanical ventilation
por: Chon, G, et al.
Publicado: (2009)

Defining severe community-acquired pneumonia: a significant barrier to improving patient outcomes
por: Balp, MM, et al.
Publicado: (2009)

Assessment of specific risk scores for patients admitted to the ICU for severe community-acquired pneumonia
por: Joya-Montosa, C, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cfvg3crorh68csle20lrejnl3i